New Expert Consensus Establishes Global Standards for Tumor Mutational Burden Testing to Enhance Immunotherapy Precision

Expert consensus published in Cancer Biology & Medicine establishes new standards for TMB testing to improve immunotherapy outcomes in real-world oncology.

By: AXL Media

Published: Mar 26, 2026, 9:00 AM EDT

Source: Information for this report was sourced from Chinese Academy of Sciences

Addressing the Precision Gap in Cancer Immunotherapy

Immune checkpoint inhibitors have revolutionized oncology, yet their effectiveness is often limited to a minority of patients. This has sparked an intensive search for predictive biomarkers, with Tumor Mutational Burden (TMB) emerging as a primary candidate. TMB measures the number of mutations within a tumor's genome, which can lead to the creation of neoantigens that alert the immune system to cancer cells. However, the clinical utility of TMB has been hampered by a lack of standardization across different laboratories. Variations in sample types, sequencing depths, and reporting styles have historically led to inconsistent results, making it difficult for oncologists to rely on TMB as a definitive guide for treatment.

Standardizing the Technical Framework for TMB Detection

The new expert consensus, led by the Chinese Academy of Sciences and the East China Lung Cancer Group, establishes whole-exome sequencing as the gold standard for TMB detection. Recognizing the practical limitations of clinical settings, the guidance also validates targeted panel sequencing, provided it covers at least 1.0 Mb of the genome. To ensure accuracy, the experts recommend a sequencing depth of at least 200× and the use of standardized bioinformatics pipelines capable of filtering out germline variants. These technical benchmarks are designed to reduce platform-related bias and ensure that TMB values remain comparable across different medical institutions.

The Shift from Universal to Cancer-Specific Thresholds

One of the most significant shifts introduced by the consensus is the rejection of a universal "high versus low" TMB threshold. Data indicates that TMB values vary dramatically depending on the specific type of cancer. For example, lung cancers often exhibit higher mutational loads than other solid tumors. The new framework argues that clinically useful cutoffs must be linked to actual immunotherapy outcomes within specific cancer types rather than arbitrary statistical divisions. This nuanced approach moves the field toward a more sophisticated model where the context of the disease shapes the interpretation of the biomarker.